bioaccess® vs Israel

You picked Israel. Keep it if it is moving. If you need a second country, bioaccess® runs first-in-human across Latin America from Miami: first-patient timing varies by study (we confirm it per protocol), ethics review timed to each committee's meeting schedule, and a study-specific budget quote. There is no published Israel start-up median. Ask for a study-specific calendar. Foreign device data is eligible for FDA submission and review under 21 CFR 812.28 when GCP / ISO 14155, ethics, and consent are met. Eligibility is not clearance or approval.

Built for

Not the right fit if

Head-to-head: bioaccess® vs Israel

Metricbioaccess®Israel
Role in your planCountry 2 / the rescue path — U.S. regulatory anchoring + Latin American execution from MiamiCountry 1 — the destination you already picked. bioaccess® is not a CRO in Israel
Start-up clockFirst-patient timing varies by study (we confirm it per protocol). Ethics review timed to each committee's meeting schedule. For device studies, Argentina's ANMAT reviews under Disposition 969/1997 (its regime for medical technology clinical studies), which allows up to 90 business days (ANMAT Disp. 969/1997, https://servicios.infoleg.gob.ar/infolegInternet/anexos/40000-44999/42205/norma.htm) from filing for a decision; objections pause the clockThere is no published Israel start-up median. Ask for a study-specific calendar
Per-patient costSee sample budget.No published US per-patient benchmark
EntityNone to stand up — contract and startbioaccess® does not claim an Israeli legal entity
FDA acceptance & data applicabilityData conducted under GCP (ISO 14155 for devices; ICH E6 for drugs) is eligible for FDA submission and review under 21 CFR 812.28 or 312.120. Eligibility is not clearance or approvalAlso eligible when GCP, ethics, and consent are met. FDA and PMDA assess data applicability case-by-case, regardless of whether the trial runs in Latin America, Australia, or Canada — the same rule applies if country 1 is Israel
Distance & time zone from the U.S.Same or adjacent U.S. time zones; ~3–8 hour flights (see the Australia comparison)There is no published Miami–Israel flight-hour figure
Where it is genuinely strongerLowest cash-basis LATAM cost, no foreign entity, same region for later patient-phase workIt is the country you already picked. If that file is moving, stay on it

Comparison uses widely-known category facts about Israel and published US benchmark ranges — not Israel-specific figures. bioaccess® figures reflect our FIH-12™ operating model.

Why bioaccess® for first-in-human

You picked Israel. That is a real first-in-human destination. We will not talk you out of it. It answers the next question: what if country 1 stalls, queues, or does not give you a dataset you can take to FDA or to a raise.

bioaccess® is the First-in-Human CRO. Miami headquarters. U.S. regulatory anchoring plus Latin American execution. bioaccess® does not claim an Israeli legal entity. There is no published Israel start-up median. Ask for a study-specific calendar. The clocks we will repeat are already public: first-patient timing varies by study (we confirm it per protocol), ethics review timed to each committee's meeting schedule, and a study-specific budget quote.

Foreign device data is eligible for FDA submission and review under 21 CFR 812.28 when GCP / ISO 14155, ethics, and consent are met. Eligibility is not clearance or approval. FDA and PMDA assess whether foreign data apply to their populations case-by-case — that question does not turn on whether you run in Latin America, Australia, or Canada, and it does not turn on Israel either.

If Israel is moving, stay. If you need country 2, Latin America is the rescue path. Book a 30-minute feasibility call. You leave with a country, a timeline, and a budget read — not a pitch.

Frequently asked questions

Is this a CRO-in-Israel page?

No. You already picked Israel as country 1. bioaccess® is the First-in-Human CRO — Miami headquarters, U.S. regulatory anchoring plus Latin American execution. Latin America is country 2 / the rescue path. bioaccess® does not claim an Israeli legal entity.

How long does first-in-human start-up take in Israel?

There is no published Israel start-up median. Ask for a study-specific calendar. The clocks we publish are Latin American: first-patient timing varies by study (we confirm it per protocol) and ethics review timed to each committee's meeting schedule.

Will the FDA accept Latin American data after an Israel first-in-human?

Foreign clinical data from either region can support a U.S. submission when it meets the applicable requirements (21 CFR 812.28 for devices, 21 CFR 312.120 for drugs, conducted under GCP). Acceptance is determined by the FDA case-by-case, not by the country of origin. Eligibility is not clearance or approval. FDA and PMDA assess data applicability case-by-case regardless of whether the trial runs in Latin America, Australia, or Canada — the same rule applies if country 1 is Israel.

You might prefer Israel if…

Israel is the only geography your protocol and regulatory plan will accept, and that file is moving. Stay. bioaccess® is the better fit when you need a second country — cash-basis LATAM cost, no foreign entity, first-patient timing varies by study (we confirm it per protocol) — without relying on an unpublished Israel clock.

All CRO comparisons · First-in-Human CRO · Clinical Trials in Panama · Book a free 30-min strategy call